rhGH treatment administered post-stroke significantly increased insulin-like growth factor 1 (IGF-1) (Saline treatment 289.9 ± 36.14 versus rhGH treatment 433.5 ± 44.2 ng/mL, 49.51%, p < 0.0001) and IGFBP-3 (Saline treatment 254.3 ± 50.06 versus rhGH treatment 293.7 ± 26.1 ng/mL, 15.49%, p = 0.0405) levels in plasma, assessed at time of sacrifice. The gene discussed is IGF1; the disease is stroke disorder.